Discontinued — last reported Q3 '22
Parker-Hannifin Acquisitions decreased by 100.0% to $0.00 in Q4 2025 compared to the prior quarter.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
cf_acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $7.15B | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.01B | $0.00 |
| QoQ Change | — | — | — | — | — | — | -100.0% | — | — | — | — | — | — | — | — | — | -100.0% |
| YoY Change | — | — | — | — | — | — | — | — | — | -100.0% | — | — | — | — | — | — | — |
We use cookies for analytics. See our Privacy and Cookie Policy.